ABCL's logo.
Ticker Symbol: ABCL

AbCellera Biologics Inc

$16.36 - 02-10-2024 4 p.m. ET

Exchange: NASDAQ Country: CA Currency: USD Asset Type: Common Stock CIK:0001703057

Company Profile

abcellera is a canadian biotechnology company focused on accelerating the discovery of monoclonal antibody (mabs) therapeutics. antibodies are molecules that are naturally produced by the immune system of humans or animals to fight off infection and disease. the unique property of antibodies is that they can specifically recognize and target diseased cells or pathogens, making them precise and highly effective drugs with low side effects for the treatment of cancer, autoimmune disorders and infections. the immune system is capable of making billions to trillions of unique antibodies, each produced by a single immune cell. of these, only a select few are suitable for therapeutic applications. finding these rare antibodies presents a major roadblock in the development of new therapeutics. abcellera addresses this bottleneck by using microfluidic technology for the rapid and high-throughput analysis of antibodies directly from single cells. abcellera is a spinoff from dr. carl hansen’

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 2215 Yukon Street
Website: abcellera.com
CEO: Carl L.G. Hansen
Tags: N/A

Pricing

Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $4.32
Change: $0.03 ( 0.70%)
Days Range: $4.26 - $4.34
Beta: 0.97
52wk. High: $14.97
52wk. Low: $3.92
Ytd. Change -56.66%
50 Day Moving Average: $4.76
200 Day Moving Average: $6.21
Shares Outstanding: 289355867

Valuation

Market Cap: 125.0B
PE Ratio: -18.12
EPS (TTM): -0.2384

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A